CLDX
Celldex Therapeutics, Inc.
Biotechnology · Healthcare · United States
30.10
close · 2026-10-30
value
57
cheaper than peers57
quality
47
stronger fundamentals47
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 3 years ago | -8.0% | 68 |
| cash flow yield, 2 years ago | -4.6% | 66 |
| earnings yield, 2 years ago | -9.7% | 65 |
| earnings yield, 1 year ago | -8.1% | 64 |
| cash flow yield, 3 years ago | -4.5% | 62 |
| cash flow yield, 1 year ago | -6.8% | 60 |
| cash flow yield, latest year | -9.0% | 51 |
| price to book | 3.31× | 50 |
| earnings yield, latest year | -13.0% | 49 |
| price to sales | 2732.65× | 2 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 0.4% | 97 |
| return on equity | -48.9% | 49 |
| revenue growth | -97.8% | 1 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | -$126.3M |
| employees | 198 |
| first trade | 1986-05-15 |
| next earnings | not reported |
| fundamentals updated | 2026-07-27 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -3.90 | -2.45 | -2.92 | -2.40 |
| free cash flow | -$213.7M | -$159.7M | -$109.1M | -$105.6M |
| net income | -$258.8M | -$157.9M | -$141.4M | -$112.3M |
| revenue | $1.5M | $7.0M | $6.9M | $2.4M |
| unusual items | $28.6M | $37.2M | $613,000 | -$5.2M |